TotalMarketCap

Viridian Therapeutics

VRDNNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$3.241 B

$28.54 -1.77%

Close of 6 Nov 2026

As of 6 Nov 2026, Viridian Therapeutics (VRDN) has a market capitalization of $3.24B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$342.6M

Loss-making

Shares outstanding

113,558,449

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #71Enliven TherapeuticsELVN$3.28B
  2. #72Dyne TherapeuticsDYN$3.25B
  3. #73Viridian TherapeuticsVRDN$3.24B
  4. #74Telix PharmaceuticalsTLX$3.19B
  5. #75Bausch Health CompaniesBHC$2.99B

What if Viridian Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$248,654.98

Per share 8,713× higher

Bitcoin $1.53T

$13,454.29

Per share 471× higher

Apple $5.02T

$44,169.17

Per share 1,548× higher

Or at a round number

$5.00B$10.0B$20.0B$50.0B

Where these numbers come from

Share counts and financials for Viridian Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.